VIROMICS GMBH has a total of 13 patent applications. Its first patent ever was published in 2001. It filed its patents most often in Germany, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are GALEN BIO INC, IMMODULON THERAPEUTICS LTD and INNATE IMMUNOTHERAPEUTICS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Germany | 5 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Australia | 2 | |
#4 | Canada | 1 | |
#5 | Japan | 1 | |
#6 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Climate change adaptation technologies | |
#4 | Peptides | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Schubert Ulrich | 12 |
#2 | Will Hans | 7 |
#3 | Tessmer Uwe | 6 |
#4 | Schubert Evelyn | 6 |
#5 | Sirma Hueseyin | 4 |
#6 | Hohenberg Heinz | 3 |
#7 | Prassolow Alexij | 3 |
#8 | Welker Reinhold | 3 |
#9 | Lucas Kerstin | 2 |
#10 | Schubert Evelyn Dr | 1 |
Publication | Filing date | Title |
---|---|---|
DE10361944A1 | Agent for inhibiting virus replication by regulating protein folding | |
DE10361945A1 | Pharmaceutical preparation for the treatment of e.g. severe acute respiratory syndrome | |
DE10316735A1 | Inhibiting release, maturation and replication of Flaviviridae family viruses, e.g. for the treatment of hepatitis C virus infections, using proteasome inhibitor such as lactacystine or epoxomicin | |
DE10304202A1 | New Trojan proteosome or assembly inhibitors, useful for selective treatment of e.g. viral infections, particularly human immune deficiency virus, and tumors | |
DE10149398A1 | Composition for treating viral infections, especially caused by retro- or hepatitis viruses, comprises proteosome inhibitor that prevents release, maturation or replication |